Orpea Past Earnings Performance

Past criteria checks 0/6

Orpea's earnings have been declining at an average annual rate of -85.5%, while the Healthcare industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 7.9% per year.

Key information

-85.5%

Earnings growth rate

-85.5%

EPS growth rate

Healthcare Industry Growth	15.7%
Revenue growth rate	7.9%
Return on equity	n/a
Net Margin	-83.8%
Last Earnings Update	30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Orpea makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:OPA1 Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings
30 Jun 23	4,926	-4,128
31 Mar 23	4,803	-4,078
31 Dec 22	4,681	-4,027
30 Sep 22	4,602	-2,167
30 Jun 22	4,524	-307
31 Mar 22	4,411	-121
31 Dec 21	4,299	65
30 Sep 21	4,193	127
30 Jun 21	4,088	189
31 Mar 21	4,005	175
31 Dec 20	3,922	160
30 Sep 20	3,863	176
30 Jun 20	3,804	192
31 Mar 20	3,772	213
31 Dec 19	3,740	234
30 Sep 19	3,661	231
30 Jun 19	3,581	227
31 Mar 19	3,501	224
31 Dec 18	3,420	220
30 Sep 18	3,356	230
30 Jun 18	3,292	239
31 Mar 18	3,215	164
31 Dec 17	3,138	90
30 Sep 17	3,062	133
30 Jun 17	2,986	176
31 Mar 17	2,914	235
31 Dec 16	2,841	294
30 Sep 16	2,745	220
30 Jun 16	2,650	147
31 Mar 16	2,521	137
31 Dec 15	2,392	127
30 Sep 15	2,286	128
30 Jun 15	2,180	130
31 Mar 15	2,064	126
31 Dec 14	1,949	121
30 Sep 14	1,832	112
30 Jun 14	1,716	103
31 Mar 14	1,662	108
31 Dec 13	1,608	114
30 Sep 13	1,567	109
30 Jun 13	1,527	103

Quality Earnings: OPA1 is currently unprofitable.

Growing Profit Margin: OPA1 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: OPA1 is unprofitable, and losses have increased over the past 5 years at a rate of 85.5% per year.

Accelerating Growth: Unable to compare OPA1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPA1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.5%).

Return on Equity

High ROE: OPA1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Orpea Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First half 2023 earnings released: €5.74 loss per share (vs €4.17 loss in 1H 2022)

Orpea SA to Report First Half, 2023 Results on Oct 11, 2023

Full year 2022 earnings released: €62.33 loss per share (vs €1.01 profit in FY 2021)

First half 2022 earnings released: EPS: €0 (vs €1.59 in 1H 2021)

Full year 2021 earnings released: EPS: €1.01 (vs €2.48 in FY 2020)

Orpea SA to Report First Half, 2022 Results on Sep 21, 2022

Recent updates

Orpea SA has completed a Follow-on Equity Offering in the amount of €390.019673 million.

Orpea SA announced that it expects to receive €390.019673 million in funding

Orpea SA announced that it expects to receive €390.019673 million in funding

Orpea SA announced that it expects to receive €390.019673 million in funding

Orpea Sa Appoints Méka Brunel as Independent Non-Executive Director

Orpea SA has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Now 83% undervalued after recent price drop

Orpea SA(ENXTPA:ORPDS) dropped from SBF 120 Index

Orpea SA has filed a Follow-on Equity Offering in the amount of €3.884212 billion.

Orpea SA, Annual General Meeting, Dec 22, 2023

Orpea SA Provides Earnings Guidance for the Full Year 2023; Provides Consolidated Revenue Guidance for the Years 2024 and 2025

First half 2023 earnings released: €5.74 loss per share (vs €4.17 loss in 1H 2022)

New minor risk - Financial position

New major risk - Revenue and earnings growth

Orpea SA to Report First Half, 2023 Results on Oct 11, 2023

An Unknown buyer acquired portfolio of four recently built retirement homes In Austria from Orpea SA (ENXTPA:ORP) for €55 million.

An Unknown buyer acquired portfolio of four recently built retirement homes In Austria from Orpea SA (ENXTPA:ORP) for €55 million.

Orpea SA Provides Financial Guidance for 2023

Now 25% undervalued after recent price drop

New major risk - Negative shareholders equity

Full year 2022 earnings released: €62.33 loss per share (vs €1.01 profit in FY 2021)

Adoro SIA signed an agreement to acquire Retirement Home and Entire Scope of Activities in Latvia from Orpea SA (ENXTPA:ORP).

Caisse des Dépôts et Consignations and a representative group of creditors agreed to acquire a 50.2% stake in Carver Maritime Manatee.

Now 29% undervalued after recent price drop

Orpea Sa Announces Revenue Guidance for Year Ending 31 December 2022

First half 2022 earnings released: EPS: €0 (vs €1.59 in 1H 2021)

Orpea SA(ENXTPA:ORP) dropped from FTSE All-World Index (USD)

Investor sentiment deteriorated over the past week

Orpea S.A Appoints Laure Duhot as Non-Executive Director

Syntrus Achmea Real Estate & Finance signed agreement to acquire portfolio of 32 retirement homes located in the Netherlands from Orpea SA (ENXTPA:ORP) for EUR 125 million.

ORPEA Announces Major Changes in its Board of Directors

Full year 2021 earnings released: EPS: €1.01 (vs €2.48 in FY 2020)

Orpea SA to Report First Half, 2022 Results on Sep 21, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

ORPEA Appoints Laurent Guillot as CEO

Orpea Announces CEO Changes

Investor sentiment deteriorated over the past week

Orpea Provides Earnings Guidance for the Full Year 2021

First half 2021 earnings released

Upcoming dividend of €0.90 per share

Orpea SA Reiterate Revenue Guidance for the Full Year of Fiscal 2021

Full year 2020 earnings released

Orpea SA Proposes Dividend for Financial Year 2020

New 90-day low: €98.92

Orpea SA to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day high: €109

ORPEA Société Anonyme (ENXTPA:ORP) agreed to acquire remaining 55% stake in Groupe Sinoue - Sarl.

Orpea SA (ENXTPA:ORP) acquired 50% stake in Brindley Healthcare Limited.

New 90-day low - €99.32

New 90-day high - €109

Icade SA (ENXTPA : ICAD) agreed to acquire Portfolio of 9 Healthcare Facilities in Germany & France from Orpea SA (ENXTPA : ORP) for €145 million.

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta